Acrux (ACR) reported that Eli Lilly has received approval to market Axiron® in Canada, the first market outside the United States. Health Canada has granted Lilly a marketing authorisation for Axiron as testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). Acrux expects to begin earning royalties on net sales of Axiron in Canada during the 2012/13 financial year. Regulatory decisions on marketing applications under review in Australia and select European countries are anticipated during 2012.
Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin. Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents. Acrux has two products marketed by licensees in the USA, two products approved in Europe, one product in registration in the USA and further products at earlier stages of development.